Charles Hemenway, PhD


Pediatric Hematology/Oncology
Director, M.D./Ph.D. Program, Division Director, Pediatric Hematology/Oncology

Languages Spoken

English, French

Clinical Expertise

  • Anemia in Children and Adolescents
  • Bleeding Disorders in Children and Adolescents
  • Cancer in Children and Adolescents

About Dr. Hemenway

Dogs, Hiking, Fishing, Skiing

Medical Education

Medical School
University of Massachusetts Medical School
University of Florida - Internal Medicine & Pediatrics
Duke University Medical Center - Pediatrics: Pediatric Hematology-Oncology

Board Certification

Pediatric Hematology-Oncology - Subspecialty Cert: AM Board of Pediatrics


  • Degree of Recruitment of DOT1L to MLL-AF9 Defines Level of H3K79 Di- and Tri-methylation on Target Genes and Transformation Potential Kuntimaddi, A.; Achille, N. J.; Thorpe, J.; Lokken, A. A.; Singh, R.; Hemenway, C. S.; Adli, M.; Zeleznik-Le, N. J.; Bushweller, J. H., Cell reports
  • An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias Barretto, N. N.; Karahalios, D. S.; You, D.; Hemenway, C. S., Journal of experimental therapeutics & oncology
  • Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4 Lokken, A. A.; Achille, N. J.; Chang, M. J.; Lin, J. J.; Kuntimaddi, A.; Leach, B. I.; Malik, B.; Nesbit, J. B.; Zhang, S.; Bushweller, J. H.; Zeleznik-Le, N. J.; Hemenway, C. S., Leukemia research
View All ResearchShow Less
  • CBX8 a component of the Polycomb PRC1 complex, modulates DOT1L-mediated gene expression through AF9/MLLT3, Malik, B.; Hemenway, C. S., FEBS letters
  • Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes Chang, M. J.; Wu, H.; Achille, N. J.; Reisenauer, M. R.; Chou, C. W.; Zeleznik-Le, N. J.; Hemenway, C. S.; Zhang, W., Cancer research
  • Hsp90 directly modulates the spatial distribution of AF9/MLLT3 and affects target gene expression. Lin, J. J.; Hemenway, C. S., Journal of Biological Chemistry
  • Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents. Bennett, C. A.; Winters, A. C.; Barretto, N. N.; Hemenway, C. S., Leukemia research
  • The AF4-mimetic peptide PFWT, induces necrotic cell death in MV4-11 leukemia cells., Palermo, C. M.; Bennett, C. A.; Winters, A. C.; Hemenway, C. S., Leukemia research
  • Hurricane Katrina's impact on pediatric and adult patients with sickle cell disease. Karras, N. A.; Hemenway, C. S., Journal of Health Care for the Poor & Underserved
  • Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. Zhang, W.; Xia, X.; Reisenauer, M. R.; Hemenway, C. S.; Kone, B. C., Journal of Biological Chemistry
  • Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases Reiser, J.; Zhang, X. Y.; Hemenway, C. S.; Mondal, D.; Pradhan, L.; La Russa, V. F., Expert Opinion on Biological Therapy
  • MLL fusion partners AF4 and AF9 interact at subnuclear foci Erfurth, F.; Hemenway, C. S.; de Erkenez, A. C.; Domer, P. H., Leukemia
  • The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells Srinivasan, R. S.; Nesbit, J. B.; Marrero, L.; Erfurth, F.; LaRussa, V. F.; Hemenway, C. S., Leukemia
  • The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor Srinivasan, R. S.; de Erkenez, A. C.; Hemenway, C. S., Oncogene
  • The polycomb protein MPc3 interacts with AF9 an MLL fusion partner in t(9;11)(p22;q23) acute leukemias, Hemenway, C. S.; de Erkenez, A. C.; Gould, G. C., Oncogene
  • Identification and analysis of a third mouse Polycomb gene MPc3, Hemenway, C. S.; Halligan, B. W.; Gould, G. C.; Levy, L. S., Gene